• Japanese
  • Korean
  • Chinese
Cover Image

Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential

Abstract

Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential

Summary

GBI Research, the leading business intelligence provider, has released its latest report, "Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential", which provides key data, information and analysis for the global antibacterials market (covering tuberculosis, pneumonia, urinary tract infections, atypical bronchitis, tonsillitis, sinusitis and otitis media in the US, the top five countries in Europe and Japan).

This report offers a comprehensive insight into antibacterial market based on the seven indications covered. It provides a disease overview for each indication, market forecasting, drivers and barriers, key marketed products, pipeline information and deals information for each disease in the top seven markets, as well as profiles for the main companies operating in the market.

The report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts to provide a comprehensive view of the antibacterials market.

The market is large and established, but still seeing good growth despite this due to the increasing problem of nosocomial infection and the increasing incidence of some bacterial diseases in the developed world. Despite several patent expiries, including of Levaquin, one of the highest selling antibacterials, growth will continue over the forecast period. Antibacterial stewardship programs for general practitioners and hospitals, aimed at countering the development of resistance in bacteria, will not significantly slow revenues in the forecast period. While the development of new antibacterials is not currently a hugely dynamic area, targeting multi-drug resistant TB and other indications will require innovative solutions in the future.

The antibacterials market is expected to reach $12.7 billion in 2017, growing from $11.3 billion in 2010 at a CAGR of 1.7%. The market is well served currently and patent expiries are slowing the overall growth. However, despite this saturation, hospital-acquired infections are providing an impetus to development.

Scope

  • Overview of the global market for antibacterials.
  • Breakdown of the market by region.
  • Market analysis for each indication - including disease overviews, market forecasting, annual cost of therapy, treatment usage patterns, key marketed products and drivers and barriers.
  • Comprehensive pipeline analysis by indications across all phases of development.
  • Company profiles including SWOT analysis for major companies operating in the market.
  • Key deals in the antibacterials space.

Reasons to buy

  • Make more informed business decisions from the insightful and in-depth analysis of the antibacterials market.
  • Identify the opportunities and challenges that exist within the antibacterials market.
  • Build effective strategies to launch pipeline products.
  • Identify the opportunities for collaboration with the participants in the antibacterials market.

TOC

1 Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 10
  • 1.2 List of Figures 12

2 Antibacterials - Introduction 14

3 Antibacterials - Overview 15

  • 3.1 Bacterial Classification 15
    • 3.1.1 Antimicrobial Spectrum 15
    • 3.1.2 Bacterial Resistance 16
  • 3.2 Antibacterial Classification 16
    • 3.2.1 Cephalosporin Antibacterials 16
    • 3.2.2 Penicillin Antibacterials 19
    • 3.2.3 Quinolone Antibacterials 20
    • 3.2.4 Macrolide Antibacterials 21
  • 3.3 Global Revenues for Antibacterials 21
    • 3.3.1 Global Revenue and Forecast 21
    • 3.3.2 Revenue Share by Indication 23
  • 3.4 The US 24
    • 3.4.1 Total Revenues 24
  • 3.5 Europe (The UK, France, Germany, Spain, Italy) 25
    • 3.5.1 Total Revenues 25
  • 3.6 Japan 27
    • 3.6.1 Total Revenues 27
  • 3.7 Drivers and Barriers for the Antibacterials Market 28
    • 3.7.1 Drivers for the Antibacterials Market 28
    • 3.7.2 Barriers for the Antibacterials Market 28
  • 3.8 Opportunities 31
    • 3.8.1 Alliances with Academic and Research Institutions are the Way Forward for Big Pharma 31

4 Tuberculosis 32

  • 4.1 Overview 32
    • 4.1.1 Microbiology 33
    • 4.1.2 Diagnosis 33
    • 4.1.3 Treatment 33
    • 4.1.4 Prevention 34
  • 4.2 Tuberculosis Therapeutics Market Size 35
    • 4.2.1 Total Revenue 35
    • 4.2.2 Average Annual Cost of Treatment (ACT) 38
    • 4.2.3 Treatment Usage Patterns 39
  • 4.3 Drivers and Barriers for the Tuberculosis Therapeutics Market 42
    • 4.3.1 Drivers for the Tuberculosis Therapeutics Market 42
    • 4.3.2 Barriers to the Tuberculosis Therapeutics Market 43
  • 4.4 Product Profile of the Major Marketed Products in the Tuberculosis Market 43
    • 4.4.1 Isoniazid (Isonicotinylhydrazine, INH) 43
    • 4.4.2 Rifampin (RIF) 44
    • 4.4.3 Pyrazinamide (PZA) 44
    • 4.4.4 Ethambutol (EMB) 45

5 Pneumonia 46

  • 5.1 Overview 46
    • 5.1.1 Microbiology 46
    • 5.1.2 Diagnosis 46
    • 5.1.3 Treatment 47
    • 5.1.4 Prevention 48
  • 5.2 Pneumonia Therapeutics Market Size 49
    • 5.2.1 Total Revenue 49
    • 5.2.2 Annual Cost of Treatment (ACT) 52
    • 5.2.3 Treatment Usage Patterns 53
  • 5.3 Drivers and Barriers to the Pneumonia Therapeutics Market 55
    • 5.3.1 Drivers for the Pneumonia Therapeutics Market 55
    • 5.3.2 Barriers to the Pneumonia Antibacterials Market 55
  • 5.4 Product Profile of the Major Marketed Products in the Pneumonia Antibacterials Market 57
    • 5.4.1 Zyvox (linezolid) 57
    • 5.4.2 Zosyn (piperacillin and tazobactum) 58
    • 5.4.3 Levaquin (levofloxacin) 58
    • 5.4.4 Avelox (moxifloxacin) 59
    • 5.4.5 Omnicef (cefnidir) 59
    • 5.4.6 Tygacil (tigecycline) 60
    • 5.4.7 Doribax (doripenem) 61

6 Urinary Tract Infections 62

  • 6.1 Overview 62
    • 6.1.1 Cystitis 62
    • 6.1.2 Urethritis 62
    • 6.1.3 Pyelonephritis 62
    • 6.1.4 Microbiology 62
    • 6.1.5 Diagnosis 62
    • 6.1.6 Urinalysis 62
    • 6.1.7 Urine Culture 62
    • 6.1.8 Treatment 63
    • 6.1.9 Prevention 64
  • 6.2 Urinary Tract Infection Therapeutics Market Size 64
    • 6.2.1 Total Revenue 64
    • 6.2.2 Annual Cost of Treatment (ACT) 67
    • 6.2.3 Treatment Usage Patterns 68
  • 6.3 Drivers and Barriers for the Urinary Tract Infection Therapeutics Market 70
    • 6.3.1 Drivers for the UTI Therapeutics Market 70
    • 6.3.2 Barriers for the UTI Therapeutics Market 70
  • 6.4 Product Profile of the Major Marketed Products in the Urinary Tract Infection Market 71
    • 6.4.1 Doribax (doripenem) 71
    • 6.4.2 Ciprofloxacin 72
    • 6.4.3 Levaquin (levafloxacin) 73
    • 6.4.4 Monurol (fosfomycin tromethamine) 74
    • 6.4.5 Macrobid (nitrofurantoin) 74

7 Atypical Bronchitis 76

  • 7.1 Overview 76
    • 7.1.1 Microbiology 76
    • 7.1.2 Diagnosis 76
    • 7.1.3 Treatment 76
    • 7.1.4 Prevention 76
  • 7.2 Atypical Bronchitis Therapeutics Market Size 77
    • 7.2.1 Total Revenue 77
    • 7.2.2 Annual Cost of Treatment (ACT) 79
    • 7.2.3 Treatment Usage Patterns 80
  • 7.3 Drivers and Barriers for the Atypical Bronchitis Therapeutics Market 82
    • 7.3.1 Drivers for the Atypical Bronchitis Therapeutics Market 82
    • 7.3.2 Barriers for the Atypical Bronchitis Therapeutics Market 82
  • 7.4 Marketed Products 83

8 Tonsillitis 84

  • 8.1 Overview 84
    • 8.1.1 Microbiology 84
    • 8.1.2 Diagnosis 84
    • 8.1.3 Treatment 84
    • 8.1.4 Prevention 85
  • 8.2 Tonsillitis Therapeutics Market Size 85
    • 8.2.1 Total Revenue 85
    • 8.2.2 Annual Cost of Treatment (ACT) 87
    • 8.2.3 Treatment Usage Patterns 88
  • 8.3 Drivers and Barriers for the Tonsillitis Therapeutics Market 90
    • 8.3.1 Drivers for the Tonsillitis Therapeutics Market 90
    • 8.3.2 Barriers for the Tonsillitis Therapeutics Market 90
  • 8.4 Marketed Products 91
    • 8.4.1 Spectracef 91

9 Sinusitis 92

  • 9.1 Overview 92
    • 9.1.1 Frontal Sinusitis (located behind the forehead) 92
    • 9.1.2 Ethmoid Sinusitis (behind the bridge of the nose) 92
    • 9.1.3 Sphenoid Sinusitis (behind the eyes) 92
    • 9.1.4 Maxillary Sinusitis (behind the cheeks) 92
    • 9.1.5 Acute Sinusitis 92
    • 9.1.6 Chronic Sinusitis 92
    • 9.1.7 Microbiology 93
    • 9.1.8 Diagnosis 93
    • 9.1.9 Treatment 93
    • 9.1.10 Prevention 93
  • 9.2 Sinusitis Therapeutics Market Size 94
    • 9.2.1 Total Revenue 94
    • 9.2.2 Annual Cost of Therapy 96
    • 9.2.3 Therapeutic Patterns 97
  • 9.3 Drivers and Barriers for the Sinusitis Therapeutics Market 98
    • 9.3.1 Drivers for the Sinusitis Therapeutics Market 98
    • 9.3.2 Barriers for the Sinusitis Therapeutics Market 99
  • 9.4 Marketed Products 99
    • 9.4.1 Augmentin 99
    • 9.4.2 Levaquin 100
    • 9.4.3 Doryx 101

10 Otitis Media 102

  • 10.1 Overview 102
    • 10.1.1 Acute 102
    • 10.1.2 Serous 102
    • 10.1.3 Chronic Suppurative 102
  • 10.2 Otitis Media Therapeutics Market Size 103
    • 10.2.1 Total Revenue 103
    • 10.2.2 Annual Cost of Therapy 105
    • 10.2.3 Therapeutic Patterns 106
  • 10.3 Drivers and Barriers for the Otitis Media Therapeutics Market 107
    • 10.3.1 Drivers for the Otitis Media Therapeutics Market 107
    • 10.3.2 Barriers for the Otitis Media Therapeutics Market 107
  • 10.4 Marketed Products 108
    • 10.4.1 Amoxicillin 108

11 Antibacterials - Pipeline Analysis 109

  • 11.1 Introduction 109
  • 11.2 Global Tuberculosis Market: Pipeline Analysis 110
    • 11.2.1 Overview 110
    • 11.2.2 Research and Development Pipeline - Phase III 110
    • 11.2.3 Research and Development Pipeline - Phase II 111
    • 11.2.4 Research and Development Pipeline - Phase I 112
    • 11.2.5 Research and Development Pipeline - Preclinical 112
  • 11.3 Global Pneumonia Therapeutics Market: Pipeline Assessment 113
    • 11.3.1 Overview 113
    • 11.3.2 NDA Filed 113
    • 11.3.3 Phase III 113
    • 11.3.4 Phase II 114
    • 11.3.5 Phase I 115
    • 11.3.6 Preclinical 115
  • 11.4 Global Urinary Tract Infection Therapeutics Market: Pipeline Assessment 116
    • 11.4.1 Overview 116
    • 11.4.2 Phase III 116
    • 11.4.3 Phase II 117
    • 11.4.4 Phase I 117
    • 11.4.5 Discovery 117
  • 11.5 Global Atypical Bronchitis Therapeutics Market: Pipeline Assessment 118
    • 11.5.1 Phase I 118
  • 11.6 Global Tonsillitis Therapeutics Market: Pipeline Assessment 118
    • 11.6.1 Overview 118
  • 11.7 Global Sinusitis Therapeutics Market: Pipeline Assessment 118
    • 11.7.1 Phase I 118
  • 11.8 Global Otitis Media Therapeutics Market: Pipeline Assessment 119
    • 11.8.1 Overview 119
    • 11.8.2 Phase II 119
    • 11.8.3 Preclinical 119

12 Antibacterials: Competitive Landscape 120

  • 12.1 Major Players 120
  • 12.2 Major Company Profiles 120
    • 12.2.1 Pfizer 120
    • 12.2.2 Sanofi 121
    • 12.2.3 Bayer 122
    • 12.2.4 GlaxoSmithKline 123
    • 12.2.5 AstraZeneca 124
    • 12.2.6 Cubist 125
    • 12.2.7 Daiichi Sankyo 126
    • 12.2.8 Tetraphase 127
    • 12.2.9 Johnson and Johnson 128

13 Antibacterials - Strategic Consolidations 129

  • 13.1 Overview - Antibacterials Market 129
    • 13.1.1 Deals by Indication 129
    • 13.1.2 Deals by Year 130
  • 13.2 Tuberculosis 130
    • 13.2.1 Mergers and Acquisitions 130
    • 13.2.2 Licensing and Co-Developments 130
  • 13.3 Pneumonia 133
    • 13.3.1 Furiex Pharmaceuticals Enters into Licensing Agreement with Janssen Pharmaceutica for JNJ-Q2 (April 19, 2011) 133
    • 13.3.2 TaiGen Biotechnology Amends its Licensing Agreement with Warner Chilcott for Nemonoxacin (October 14, 2010) 133
    • 13.3.3 Anacor Pharmaceuticals Enters into Licensing Agreement with GlaxoSmithKline (June 29, 2010) 134
    • 13.3.4 Paratek Pharmaceuticals Enters into Licensing Agreement with Novartis (October 8, 2009) 134
    • 13.3.5 AstraZeneca Enters into Co-Development Agreement with Forest Laboratories (August 12, 2009) 134
    • 13.3.6 Protea Vaccine Enters into Co-Development Agreement with GlaxoSmithKline Biologicals (June 16, 2009) 134
    • 13.3.7 Sanofi-aventis Enters into Licensing and Collaboration Agreement with Novozymes (December 22, 2008) 135
    • 13.3.8 Laboratorios Farmaceuticos ROVI Enters into Co-Development Agreement with Sanofi Pasteur (May 5, 2008) 135
    • 13.3.9 Aridis Pharmaceuticals Enters into Licensing Agreement with University of Iowa Research (February 19, 2008) 135
    • 13.3.10 Nektar Therapeutics Enters into Co-Development Agreement with Bayer HealthCare (August 6, 2007) 135
    • 13.3.11 Oscient Pharmaceuticals Enters into License Agreement with Menarini Group for FACTIVE (January 4, 2007) 136
  • 13.4 UTI 136
    • 13.4.1 Teva Pharmaceutical Acquires CoGenesys from New Enterprise, Orbimed and Red Abbey (February 21, 2008) 136
    • 13.4.2 NanoBio Enters into Licensing Agreement with University of Michigan (April 20, 2011) 136
    • 13.4.3 Anacor Pharmaceuticals Enters into Licensing Agreement with GlaxoSmithKline (June 29, 2010) 136
    • 13.4.4 Depomed Amends Licensing Agreement with Madaus (April 30, 2009) 137
  • 13.5 Atypical Bronchitis 137
    • 13.5.1 Teva Pharmaceutical Industries Completes Acquisition of Ratiopharm (August 10, 2010) 137
  • 13.6 Tonsillitis 137
    • 13.6.1 Meiji Seika Enters into Licensing Agreement with Cornerstone Biopharma (November 9, 2006) 137
  • 13.7 Sinusitis 138
    • 13.7.1 Oscient Pharmaceuticals Enters into License Agreement with Menarini Group for FACTIVE (January 4, 2007) 138
  • 13.8 Otitis Media 138
    • 13.8.1 MerLion Pharmaceuticals Enters into Licensing Agreement with Alcon Pharmaceuticals for Finafloxacin (January 11, 2011) 138
    • 13.8.2 OctoPlus Enters into Licensing Agreement with Green Cross (November 22, 2006) 138

14 Antibacterials - Appendix 139

  • 14.1 Market Definition 139
  • 14.2 Abbreviations 139
  • 14.3 Sources 141
  • 14.4 Research Methodology 141
    • 14.4.1 Coverage 142
    • 14.4.2 Secondary Research 142
    • 14.4.3 Primary Research 142
  • 14.5 Forecasting 143
    • 14.5.1 Epidemiology-based Forecasting 143
    • 14.5.2 Expert Panels Validation 144
  • 14.6 Geographical Landscape 144
  • 14.7 Pipeline Analysis 144
  • 14.8 Competitive Landscape 144
  • 14.9 Contact Us 144
  • 14.10 Disclaimer 145

List of Tables

1.1 List of Tables

  • Table 1: Antibacterials Market, Classification, Cephalosporin Antibacterials by Generations 18
  • Table 2: Antibacterials, Classification, Penicillin Antibacterials 20
  • Table 3: Antibacterials Market, Global, Revenue, $bn, 2002-2010 21
  • Table 4: Antibacterials Market, Global, Revenue Forecasts, $bn, 2010-2017 22
  • Table 5: Antibacterials Market, The US, Revenue, $bn, 2002-2010 24
  • Table 6: Antibacterials Market, The US, Revenue Forecasts, $bn, 2010-2017 24
  • Table 7: Antibacterials Market, EU-5, Revenue, $bn, 2002-2010 25
  • Table 8: Antibacterials Market, EU-5, Revenue Forecasts, $bn, 2010-2017 25
  • Table 9: Antibacterials Market, Japan, Revenue, $m, 2002-2010 27
  • Table 10: Antibacterials Market, Japan, Revenue Forecasts, $m, 2010-2017 27
  • Table 11: Tuberculosis Therapeutics Market, Global, Revenue, $m, 2002-2010 35
  • Table 12: Tuberculosis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 35
  • Table 13: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2010 36
  • Table 14: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2010-2017 36
  • Table 15: Tuberculosis Antibacterials Market, Global, ACT, $, 2002-2010 38
  • Table 16: Tuberculosis Antibacterials Market, Global, ACT, $, 2010-2017 38
  • Table 17: Tuberculosis Therapeutics Market, Global, Prevalence Population, '000, 2002-2010 39
  • Table 18: Tuberculosis Therapeutics Market, Global, Prevalence Population, '000, 2010-2017 39
  • Table 19: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2002-2010 40
  • Table 20: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2010-2017 40
  • Table 21: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, '000, 2002-2010 41
  • Table 22: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, '000, 2010-2017 41
  • Table 23: Pneumonia Therapeutics Market, Global, Revenue, $m, 2002-2010 49
  • Table 24: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 49
  • Table 25: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2010 50
  • Table 26: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 51
  • Table 27: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 52
  • Table 28: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 52
  • Table 29: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2010 53
  • Table 30: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2010-2017 53
  • Table 31: Urinary Tract Infection Therapeutics Market, Global, Revenue, $m, 2002-2010 64
  • Table 32: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 64
  • Table 33: Urinary Tract Infection Therapeutics Market, Global, Revenue, $m, 2002-2010 65
  • Table 34: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 66
  • Table 35: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 67
  • Table 36: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 67
  • Table 37: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 68
  • Table 38: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 68
  • Table 39: Atypical Bronchitis Therapeutics Market, Global, Revenue, $m, 2002-2010 77
  • Table 40: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 77
  • Table 41: Atypical Bronchitis Therapeutics Market, Global, Revenue, $m, 2002-2010 78
  • Table 42: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 78
  • Table 43: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 79
  • Table 44: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 79
  • Table 45: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2010 80
  • Table 46: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million, 2010-2017 80
  • Table 47: Tonsillitis Therapeutics Market, Global, Revenue, $m, 2002-2010 85
  • Table 48: Tonsillitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 85
  • Table 49: Tonsillitis Therapeutics Market, Global, Revenue, $m, 2002-2010 86
  • Table 50: Tonsillitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 86
  • Table 51: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 87
  • Table 52: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 87
  • Table 53: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 88
  • Table 54: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 88
  • Table 55: Sinusitis Therapeutics Market, Global, Revenue, $bn, 2002-2010 94
  • Table 56: Sinusitis Therapeutics Market, Global, Revenue Forecasts, $bn, 2010-2017 94
  • Table 57: Sinusitis Therapeutics Market, Global, Revenue by Country, $bn 2002-2010 95
  • Table 58: Sinusitis Therapeutics Market, Global, Revenue Forecasts by Country, $bn, 2010-2017 95
  • Table 59: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 96
  • Table 60: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 96
  • Table 61: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 97
  • Table 62: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 97
  • Table 63: Otitis Media Therapeutics Market, Global, Revenue, $m, 2002-2010 103
  • Table 64: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 103
  • Table 65: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2010 104
  • Table 66: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 104
  • Table 67: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 105
  • Table 68: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 105
  • Table 69: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 106
  • Table 70: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 106
  • Table 71: Tuberculosis Therapeutics Market, Pipeline, Phase III Molecules, 2010 110
  • Table 72: Tuberculosis Therapeutics Market, Pipeline, Phase II Molecules, 2010 111
  • Table 73: Tuberculosis Therapeutics Market, Pipeline, Phase I Molecules, 2010 112
  • Table 74: Tuberculosis Therapeutics Market, Pipeline, Preclinical Molecules, 2010 112
  • Table 75: Pneumonia Therapeutics Market, Pipeline, NDA Filed Molecules, 2010 113
  • Table 76: Pneumonia Therapeutics Market, Pipeline, Phase III Molecules, 2010 113
  • Table 77: Pneumonia Therapeutics Market, Pipeline, Phase II Molecules, 2010 114
  • Table 78: Pneumonia Therapeutics Market, Pipeline, Phase I Molecules, 2010 115
  • Table 79: Pneumonia Therapeutics Market, Pipeline, Preclinical Molecules, 2010 115
  • Table 80: Urinary Tract Infection Therapeutics Market, Pipeline, Phase III Molecules, 2010 116
  • Table 81: Urinary Tract Infection Therapeutics Market, Pipeline, Phase II Molecules, 2010 117
  • Table 82: Urinary Tract Infection Therapeutics Market, Pipeline, Phase I Molecules, 2010 117
  • Table 83: Urinary Tract Infection Therapeutics Market, Pipeline, Discovery Molecules, 2010 117
  • Table 84: Atypical Bronchitis Therapeutics Market, Pipeline, Phase I Molecules, 2010 118
  • Table 85: Sinusitis Therapeutics Market, Pipeline, Phase I Molecules, 2010 118
  • Table 86: Otitis Media Therapeutics Market, Pipeline, Phase II Molecules, 2010 119
  • Table 87: Otitis Media Therapeutics Market, Pipeline, Preclinical Molecules, 2010 119

List of Figures

1.2 List of Figures

  • Figure 1: Antibacterials Market, Global, Revenue Forecasts, $bn, 2002-2017 21
  • Figure 2: Antibacterials Market, Global, Revenue Share by Indication, %, 2010 23
  • Figure 3: Antibacterials Market, The US, Revenue Forecasts, $bn, 2002-2017 24
  • Figure 4: Antibacterials Market, EU-5, Revenue Forecasts, $bn, 2002-2017 25
  • Figure 5: Antibacterials Market, Japan, Revenue Forecasts, $m, 2002-2017 27
  • Figure 6: Tuberculosis, Recommended Initial Therapy, 2011 33
  • Figure 7: Tuberculosis, Treatment Flow Pattern, 2011 34
  • Figure 8: Tuberculosis Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 35
  • Figure 9: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 36
  • Figure 10: Tuberculosis Therapeutics Market, Global, ACT, $, 2002-2017 38
  • Figure 11: Tuberculosis Therapeutics Market, Global, Prevalence Population, '000, 2002-2017 39
  • Figure 12: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2002-2017 40
  • Figure 13: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, '000, 2002-2017 41
  • Figure 14: Pneumonia Therapeutics Market, Drugs used in the Treatment of Pneumonia, 2011 48
  • Figure 15: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 49
  • Figure 16: Pneumonia Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 50
  • Figure 17: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 52
  • Figure 18: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2017 53
  • Figure 19: Urinary Tract Infection Therapeutics Market, Treatment of Uncomplicated UTI, 2011 63
  • Figure 20: Urinary Tract Infection Therapeutics Market, Treatment of Complicated UTI, 2011 63
  • Figure 21: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017 64
  • Figure 22: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 65
  • Figure 23: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 67
  • Figure 24: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 68
  • Figure 25: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017 77
  • Figure 26: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 78
  • Figure 27: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 79
  • Figure 28: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2017 80
  • Figure 29: Tonsillitis Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017 85
  • Figure 30: Tonsillitis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 86
  • Figure 31: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 87
  • Figure 32: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 88
  • Figure 33: Sinusitis Therapeutics Market, Global, Revenue Forecast, $bn, 2002-2017 94
  • Figure 34: Sinusitis Therapeutics Market, Global, Revenue Forecasts by Country, $bn, 2010-2017 95
  • Figure 35: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 96
  • Figure 36: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 97
  • Figure 37: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 103
  • Figure 38: Otitis Media Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2010-2017 104
  • Figure 39: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 105
  • Figure 40: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 106
  • Figure 41: Tuberculosis Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 110
  • Figure 42: Pneumonia Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 113
  • Figure 43: Urinary Tract Infection Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 116
  • Figure 44: Otitis Media Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 119
  • Figure 45: Antibacterial Therapeutics Market, SWOT Analysis of Pfizer, 2010 120
  • Figure 46: Antibacterial Therapeutics Market, Sanofi SWOT Profile, 2010 121
  • Figure 47: Antibacterials Market, Bayer SWOT Profile, 2010 122
  • Figure 48: Antibacterials Market, GSK SWOT Profile, 2010 123
  • Figure 49: Antibacterials Market, AstraZeneca SWOT Profile, 2010 124
  • Figure 50: Antibacterial, Cubist SWOT Profile, 2010 125
  • Figure 51: Antibacterial, Daiichi-Sankyo SWOT Profile, 2010 126
  • Figure 52: Antibacterial, Tetraphase SWOT Profile, 2010 127
  • Figure 53: Antibacterial, Johnson & Johnson SWOT Profile, 2010 128
  • Figure 54: Antibacterials Market, Global, Deals by Indication (%), 2011 129
  • Figure 55: Antibacterials Market, Global, Deals by Year (%), 2004-2011 130
Show More
Pricing